​

Johnson & Johnson (JNJ) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

JNJ Stock Forecast

Johnson & Johnson (JNJ) stock forecast, based on 38 Wall Street analysts, predicts a 12-month average price target of $207.62, with a high of $240.00 and a low of $190.00. This represents a -1.10% decline from the last price of $209.93.

$140 $160 $180 $200 $220 $240 High: $240 Avg: $207.62 Low: $190 Last Closed Price: $209.93

JNJ Stock Rating

Johnson & Johnson stock's rating consensus is Buy, based on 38 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 18 Buy (47.37%), 17 Hold (44.74%), 3 Sell (7.89%), and 0 Strong Sell (0.00%).

Buy
Total 38 0 3 17 18 Strong Sell Sell Hold Buy Strong Buy

JNJ Price Target Upside V Benchmarks

TypeNameUpside
StockJohnson & Johnson-1.10%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks7.11%

Price Target Trends

1M3M12M
# Anlaysts51618
Avg Price Target$218.20$206.00$201.33
Last Closing Price$209.93$209.93$209.93
Upside/Downside3.94%-1.87%-4.10%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 254911-125
Nov, 253911-124
Oct, 252912-124
Sep, 252814--24
Aug, 252814--24
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 12, 2025Morgan Stanley$197.00$210.60-6.46%-6.16%
Dec 11, 2025RBC Capital$230.00$206.5411.36%9.56%
Dec 10, 2025HSBC$240.00$199.9620.02%14.32%
Dec 05, 2025Guggenheim$227.00$202.4812.11%8.13%
Dec 02, 2025Barclays$197.00$205.34-4.06%-6.16%
Oct 22, 2025Ilya ZubkovJohnson Rice$190.00$193.18-1.65%-9.49%
Oct 22, 2025Ilya ZubkovLoop Capital Markets$190.00$193.18-1.65%-9.49%
Oct 15, 2025David ToungArgus Research$210.00$191.199.84%0.03%
Oct 15, 2025Raymond James$209.00$190.859.51%-0.44%
Oct 15, 2025Terence FlynnMorgan Stanley$190.00$190.85-0.45%-9.49%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 11, 2025BMO CapitalOutperformOutperformhold
Dec 11, 2025RBC CapitalOutperformOutperformhold
Dec 11, 2025CitigroupBuyBuyhold
Dec 10, 2025HSBCBuyBuyhold
Dec 05, 2025GuggenheimBuyBuyhold
Oct 22, 2025Johnson RiceOutperformHolddowngrade
Oct 20, 2025Johnson RiceBuyOutperformupgrade
Oct 15, 2025Raymond JamesOutperformOutperformhold
Oct 14, 2025Cowen & Co.BuyBuyhold
Oct 14, 2025UBSBuyBuyhold

Financial Forecast

EPS Forecast

$5 $6 $7 $8 $9 $10 $11 $12 $13 $14 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$5.59$7.93$6.86$13.88$5.84-----
Avg Forecast$8.00$9.83$10.05$9.92$9.95$10.57$11.04$11.53$12.21$12.80
High Forecast$8.08$9.94$10.16$9.95$10.09$10.62$11.42$12.49$12.51$13.11
Low Forecast$7.93$9.75$9.96$9.91$9.90$10.51$10.85$10.56$11.99$12.57
Surprise %-30.13%-19.33%-31.74%39.92%-41.31%-----

Revenue Forecast

$60B $70B $80B $90B $100B $110B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$82.58B$78.74B$79.99B$85.16B$61.35B-----
Avg Forecast$81.80B$94.45B$95.02B$84.75B$88.78B$90.30B$93.55B$97.02B$101.93B$106.16B
High Forecast$82.48B$95.24B$95.88B$84.79B$89.21B$91.53B$94.48B$97.31B$103.85B$108.15B
Low Forecast$81.26B$93.83B$94.42B$84.73B$88.58B$89.79B$92.09B$96.74B$100.50B$104.67B
Surprise %0.96%-16.63%-15.82%0.49%-30.89%-----

Net Income Forecast

$10B $16B $22B $28B $34B $40B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$14.71B$20.88B$17.94B$35.15B$14.07B-----
Avg Forecast$15.69B$17.26B$18.98B$13.33B$25.59B$27.05B$28.52B$29.51B$31.26B$32.77B
High Forecast$18.83B$20.71B$22.78B$15.99B$25.83B$27.19B$29.24B$31.98B$32.03B$33.57B
Low Forecast$12.55B$13.81B$15.19B$10.66B$25.35B$26.91B$27.79B$27.05B$30.69B$32.18B
Surprise %-6.21%20.98%-5.49%163.79%-45.03%-----

JNJ Forecast FAQ

Is Johnson & Johnson stock a buy?

Johnson & Johnson stock has a consensus rating of Buy, based on 38 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 18 Buy, 17 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Johnson & Johnson is a favorable investment for most analysts.

What is Johnson & Johnson's price target?

Johnson & Johnson's price target, set by 38 Wall Street analysts, averages $207.62 over the next 12 months. The price target range spans from $190 at the low end to $240 at the high end, suggesting a potential -1.10% change from the previous closing price of $209.93.

How does Johnson & Johnson stock forecast compare to its benchmarks?

Johnson & Johnson's stock forecast shows a -1.10% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the drug manufacturers - general stocks industry (7.11%).

What is the breakdown of analyst ratings for Johnson & Johnson over the past three months?

  • December 2025: 16.00% Strong Buy, 36.00% Buy, 44.00% Hold, 0% Sell, 4.00% Strong Sell.
  • November 2025: 12.50% Strong Buy, 37.50% Buy, 45.83% Hold, 0% Sell, 4.17% Strong Sell.
  • October 2025: 8.33% Strong Buy, 37.50% Buy, 50.00% Hold, 0% Sell, 4.17% Strong Sell.

What is Johnson & Johnson’s EPS forecast?

Johnson & Johnson's average annual EPS forecast for its fiscal year ending in December 2025 is $10.57, marking a 80.99% increase from the reported $5.84 in 2024. Estimates for the following years are $11.04 in 2026, $11.53 in 2027, $12.21 in 2028, and $12.8 in 2029.

What is Johnson & Johnson’s revenue forecast?

Johnson & Johnson's average annual revenue forecast for its fiscal year ending in December 2025 is $90.3B, reflecting a 47.19% increase from the reported $61.35B in 2024. The forecast for 2026 is $93.55B, followed by $97.02B for 2027, $101.93B for 2028, and $106.16B for 2029.

What is Johnson & Johnson’s net income forecast?

Johnson & Johnson's net income forecast for the fiscal year ending in December 2025 stands at $27.05B, representing an 92.31% increase from the reported $14.07B in 2024. Projections indicate $28.52B in 2026, $29.51B in 2027, $31.26B in 2028, and $32.77B in 2029.